|
Delayed
London S.E.
10:14:25 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 9.730 GBX | +0.31% |
|
-1.72% | -1.72% |
| 08-19 | EARNINGS AND TRADING: Cooks sales up; Amcomri profit rises, debt falls | AN |
| 08-19 | UK Regulator Allows Scancell Holdings to Launch Late-stage Trial for Advanced Melanoma Therapy | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 157M | - | ||||
| 47.86B | |||||
| 44.46B | |||||
| 41.85B | |||||
| 41.34B | - | - | - | - | - |
| 30.04B |
- Stock Market
- Stocks
- SCLP Stock
- Charts Scancell Holdings plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
